SK285908B6 - Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe - Google Patents
Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe Download PDFInfo
- Publication number
- SK285908B6 SK285908B6 SK1437-2000A SK14372000A SK285908B6 SK 285908 B6 SK285908 B6 SK 285908B6 SK 14372000 A SK14372000 A SK 14372000A SK 285908 B6 SK285908 B6 SK 285908B6
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- warm
- blooded animal
- treating
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8034798P | 1998-04-01 | 1998-04-01 | |
US11895499P | 1999-02-05 | 1999-02-05 | |
PCT/CA1999/000280 WO1999050225A1 (en) | 1998-04-01 | 1999-04-01 | Aminocyclohexyl ether compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
SK14372000A3 SK14372000A3 (sk) | 2001-07-10 |
SK285908B6 true SK285908B6 (sk) | 2007-10-04 |
Family
ID=26763394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1437-2000A SK285908B6 (sk) | 1998-04-01 | 1999-04-01 | Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe |
Country Status (33)
Country | Link |
---|---|
US (5) | US7101877B2 (pt) |
EP (2) | EP1087934B1 (pt) |
JP (2) | JP4334766B2 (pt) |
KR (1) | KR100631299B1 (pt) |
CN (1) | CN1217918C (pt) |
AT (1) | ATE260240T1 (pt) |
AU (1) | AU751772C (pt) |
BE (1) | BE2011C002I2 (pt) |
BR (1) | BRPI9909282B8 (pt) |
CA (1) | CA2326777C (pt) |
CY (1) | CY2010018I2 (pt) |
CZ (1) | CZ302147B6 (pt) |
DE (2) | DE69915063T2 (pt) |
DK (1) | DK1087934T3 (pt) |
EE (1) | EE04548B1 (pt) |
ES (1) | ES2217742T3 (pt) |
FR (1) | FR10C0057I2 (pt) |
HK (1) | HK1038345A1 (pt) |
HU (1) | HU229993B1 (pt) |
ID (1) | ID27178A (pt) |
IL (1) | IL138719A0 (pt) |
IS (1) | IS2648B (pt) |
LU (1) | LU91761I2 (pt) |
MX (1) | MXPA00009593A (pt) |
NO (2) | NO321130B1 (pt) |
NZ (1) | NZ507169A (pt) |
PL (1) | PL197293B1 (pt) |
PT (1) | PT1087934E (pt) |
RO (1) | RO121028B1 (pt) |
RU (1) | RU2252933C2 (pt) |
SK (1) | SK285908B6 (pt) |
TR (1) | TR200002796T2 (pt) |
WO (1) | WO1999050225A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751772C (en) | 1998-04-01 | 2006-09-07 | Correvio International Sàrl | Aminocyclohexyl ether compounds and uses thereof |
US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
DE10049481A1 (de) | 2000-09-29 | 2002-05-02 | Gruenenthal Gmbh | Substituierte C-Cyclohexylmethylamin-Derivate |
US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
US7524879B2 (en) * | 2000-10-06 | 2009-04-28 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
DE10213051B4 (de) * | 2002-03-23 | 2013-03-07 | Grünenthal GmbH | Substituierte 4-Aminocyclohexanole |
WO2003105756A2 (en) * | 2002-06-14 | 2003-12-24 | Johnson Matthey Pharmaceutical Materials, Inc. | Stereoselective synthesis of 1,2-disubstituted cycloalkyls |
US7345086B2 (en) | 2003-05-02 | 2008-03-18 | Cardiome Pharma Corp. | Uses of ion channel modulating compounds |
US20090041841A1 (en) * | 2003-05-02 | 2009-02-12 | Cardiome Pharma Corp. | Controlled release tablet formulations for the prevention of arrhythmias |
US20080063707A1 (en) * | 2003-05-02 | 2008-03-13 | Cardiome Pharma Corp. | Controlled release tablet formulations for the prevention of arrhythmias |
PL227937B1 (pl) | 2003-05-02 | 2018-01-31 | Cardiome Pharma Corp | Sposób wytwarzania związku typu eteru aminocykloheksylowego, związek typu eteru aminocykloheksylowego, jego kompozycja, sposób modulowania aktywności kanałów jonowych, oraz zastosowanie związku typu eteru aminocykloheksylowego do wytwarzania leku |
CN100441568C (zh) * | 2003-05-02 | 2008-12-10 | 卡迪欧梅制药公司 | 氨基环己基醚化合物和它们的用途 |
US20060094880A9 (en) * | 2003-06-04 | 2006-05-04 | Barrett Anthony G M | Synthetic process for trans-aminocyclohexyl ether compounds |
WO2005018635A2 (en) * | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
US7345087B2 (en) | 2003-10-31 | 2008-03-18 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
WO2005097203A2 (en) * | 2004-04-01 | 2005-10-20 | Cardiome Pharma Corp. | Serum protein conjugates of ion channel modulating compounds and uses thereof |
WO2005097869A1 (en) * | 2004-04-01 | 2005-10-20 | Cardiome Pharma Corp. | Polymers comprising ion channel modulating compounds and uses thereof |
WO2005094897A2 (en) * | 2004-04-01 | 2005-10-13 | Cardiome Pharma Corp. | Pegylated ion channel modulating compounds |
US7705036B2 (en) | 2004-04-01 | 2010-04-27 | Cardiome Pharma Corp. | Deuterated aminocyclohexyl ether compounds and processes for preparing same |
US8058304B2 (en) | 2004-04-01 | 2011-11-15 | Cardiome Pharma Corp. | Merged ion channel modulating compounds and uses thereof |
US7977373B2 (en) | 2004-04-01 | 2011-07-12 | Cardiome Pharma Corp. | Prodrugs of ion channel modulating compounds and uses thereof |
CA2586918C (en) | 2004-11-08 | 2021-01-19 | Cardiome Pharma Corp. | Use of ion channel modulating compounds for treating acute atrial fibrillation in a human |
US8692002B2 (en) * | 2004-11-18 | 2014-04-08 | Cardiome Pharma Corp. | Synthetic process for aminocyclohexyl ether compounds |
AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
GB0510164D0 (en) * | 2005-04-28 | 2005-06-22 | Paradigm Therapeutics Ltd | Ion channel |
MX346530B (es) | 2005-06-15 | 2017-03-22 | Cardiome Pharma Corp | Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico. |
JPWO2007055180A1 (ja) * | 2005-11-09 | 2009-04-30 | 東レ・ファインケミカル株式会社 | 光学活性トランス−2−アミノシクロヘキサノールおよびその誘導体の製造方法 |
TW200833695A (en) | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
WO2008046087A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
NZ581351A (en) * | 2007-05-04 | 2012-07-27 | Cardiome Pharma Corp | Controlled release oral formulations of vernakalant hydrochloride and related methods for preventing arrhythmia |
RU2011119626A (ru) | 2008-10-17 | 2012-11-27 | Ксенон Фармасьютикалз Инк. | Спирооксиндольные соединения и их применение в качестве терапевтичеких средств |
US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
EP2488531B1 (en) | 2009-10-14 | 2014-03-26 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
EP2605772B1 (en) | 2010-08-16 | 2016-06-22 | Cardiome International AG | Process for preparing aminocyclohexyl ether compounds |
US9681836B2 (en) | 2012-04-23 | 2017-06-20 | Cyberonics, Inc. | Methods, systems and apparatuses for detecting seizure and non-seizure states |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
CN114031535B (zh) * | 2021-11-30 | 2023-08-25 | 上海旭东海普药业有限公司 | 一种改进的盐酸维纳卡兰的合成方法 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2954380A (en) | 1958-11-26 | 1960-09-27 | Us Vitamin Pharm Corp | Piperazinocyclohexyl esters |
US3218328A (en) | 1963-02-18 | 1965-11-16 | U S Vitamin & Pharmacentical C | Heterocyclic amino phenoxyacetic acids, acid addition salts and quaternary ammonium salts thereof |
DE2259260A1 (de) | 1972-12-04 | 1974-06-06 | Merck Patent Gmbh | Neue amine |
US4179501A (en) | 1976-11-12 | 1979-12-18 | The Upjohn Company | Analgesic N-(2-aminocycloaliphatic)azidobenzamides |
US4145435A (en) | 1976-11-12 | 1979-03-20 | The Upjohn Company | 2-aminocycloaliphatic amide compounds |
DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
US4598087A (en) | 1983-12-06 | 1986-07-01 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
US4656182A (en) | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
SE8502455L (sv) | 1984-05-18 | 1985-11-19 | Glaxo Group Ltd | Aminocyklopentyletrar och deras framstellning samt farmaceutisk beredning |
US4663343A (en) | 1985-07-19 | 1987-05-05 | Warner-Lambert Company | Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds |
EP0248824B1 (en) | 1985-10-25 | 1990-01-17 | The Upjohn Company | Use of cis-n-(2 aminocycloaliphatic) benzene acetamide and benzamide for the manufacture of anticonvulsants |
US5059620A (en) | 1985-12-27 | 1991-10-22 | The Du Pont Merck Pharmaceutical Company | Aryl substituted aminomethyl benzene derivatives |
US4855316A (en) | 1988-02-18 | 1989-08-08 | Warner-Lambert Company | 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds |
US5051428A (en) | 1988-12-06 | 1991-09-24 | Warner-Lambert Company | 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics |
AU626949B2 (en) | 1988-12-06 | 1992-08-13 | Warner-Lambert Company | 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics |
US4906655A (en) | 1989-01-24 | 1990-03-06 | Warner-Lambert Company | Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents |
JPH02270864A (ja) | 1989-04-12 | 1990-11-05 | Asahi Glass Co Ltd | フルオロカルバサイクリックヌクレオシドおよびその製造法 |
ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
CA2058502A1 (en) | 1991-12-27 | 1993-06-28 | David C. Horwell | 2-amino-mono-methoxycyclohexyl amides useful as analgesics |
EP0552386A1 (en) | 1992-01-13 | 1993-07-28 | Warner-Lambert Company | 2-Amino-3 or 6-methoxycyclohexyl amide derivatives |
US5506257A (en) | 1992-03-26 | 1996-04-09 | University Of British Columbia | Aminocyclohexylamides for antiarrhythmic and anaesthetic uses |
EP0632806B1 (en) * | 1992-03-26 | 1997-07-02 | The University Of British Columbia | Aminocyclohexylamides for antiarrhythmic and anaesthetic uses |
GB9220286D0 (en) | 1992-09-25 | 1992-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US5451596A (en) * | 1992-12-29 | 1995-09-19 | Rhone Poulenc Rorer Pharmaceuticals Inc. | Cycloalkyl amine bis-aryl squalene synthase inhibitors |
US5747278A (en) | 1993-05-21 | 1998-05-05 | California Institute Of Technology | DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof |
US5492825A (en) | 1993-08-06 | 1996-02-20 | The Regents Of The University Of California | Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells |
DE69429524T2 (de) | 1993-09-24 | 2002-08-08 | Univ British Columbia | Aminocyclohexylester und ihre anwendung |
GB9406043D0 (en) | 1994-03-26 | 1994-05-18 | Smithkline Beecham Plc | Compounds |
US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
ES2167457T3 (es) | 1994-09-19 | 2002-05-16 | Fujisawa Pharmaceutical Co | Nuevo uso medicinal de un antagonista de 5ht3. |
US5556990A (en) | 1994-12-16 | 1996-09-17 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Polyarylcarbamoylaza- and -carbamoylalkanedioic acids |
EP0801683B1 (de) | 1995-02-03 | 2002-05-02 | Basf Aktiengesellschaft | Racematspaltung primärer und sekundärer heteroatomsubstituierter amine durch enzym-katalysierte acylierung |
PL328199A1 (en) | 1996-01-25 | 1999-01-18 | Schering Ag | Improved concentrated intravascular injection and infusion solutions |
US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5646151A (en) | 1996-03-08 | 1997-07-08 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
KR20000022274A (ko) | 1996-06-27 | 2000-04-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Il-8 수용체 길항제 |
US5935945A (en) | 1996-10-31 | 1999-08-10 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6399618B1 (en) | 1997-07-09 | 2002-06-04 | Cardiome Pharma Corp | Compositions and methods for modulating sexual activity |
TW536401B (en) | 1997-09-03 | 2003-06-11 | Cardiome Pharma Corp | A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain |
CN1278166A (zh) | 1997-09-26 | 2000-12-27 | 诺特兰药品公司 | 局部麻醉或抗心律不齐同时产生止痛的氨基环己酰胺的对映体混合物 |
JP3773644B2 (ja) | 1998-01-06 | 2006-05-10 | 芝府エンジニアリング株式会社 | 接点材料 |
US6013830A (en) | 1998-03-30 | 2000-01-11 | Sepracor Inc. | Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols |
AU751772C (en) * | 1998-04-01 | 2006-09-07 | Correvio International Sàrl | Aminocyclohexyl ether compounds and uses thereof |
GB9819466D0 (en) * | 1998-09-08 | 1998-10-28 | Boudriau Pierre | Automated turning module for rudderless for personal watercraft |
US6979685B1 (en) | 1999-02-12 | 2005-12-27 | Cardiome Pharma Corp. | Cycloalkyl amine compounds and uses thereof |
WO2000047547A2 (en) | 1999-02-12 | 2000-08-17 | Nortran Pharmaceuticals Inc. | Cycloalkyl amine compounds and uses thereof |
WO2000051981A1 (en) | 1999-03-04 | 2000-09-08 | Nortran Pharmaceuticals Inc. | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics |
US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
CA2268590A1 (en) | 1999-04-12 | 2000-10-12 | Nortran Pharmaceuticals Inc. | Ion channel modulating compounds and uses thereof |
ES2225553T3 (es) | 2000-04-20 | 2005-03-16 | F. Hoffmann-La Roche Ag | Derivados de pirrolidina y piperidina y su empleo para el tratamiento de trastornos neurodegenerativos. |
CA2311483A1 (en) | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
WO2003105756A2 (en) | 2002-06-14 | 2003-12-24 | Johnson Matthey Pharmaceutical Materials, Inc. | Stereoselective synthesis of 1,2-disubstituted cycloalkyls |
US20060167226A1 (en) | 2002-07-12 | 2006-07-27 | Cardiome Pharma Corp. | Mutations of voltage-gated ion channnels that allow them to express a voltage-independent phenotype and an improved method to use the same |
WO2004098525A2 (en) | 2003-05-02 | 2004-11-18 | Cardiome Pharma Corp. | Uses of ion channel modulating compounds |
PL227937B1 (pl) | 2003-05-02 | 2018-01-31 | Cardiome Pharma Corp | Sposób wytwarzania związku typu eteru aminocykloheksylowego, związek typu eteru aminocykloheksylowego, jego kompozycja, sposób modulowania aktywności kanałów jonowych, oraz zastosowanie związku typu eteru aminocykloheksylowego do wytwarzania leku |
US7345086B2 (en) | 2003-05-02 | 2008-03-18 | Cardiome Pharma Corp. | Uses of ion channel modulating compounds |
US20060094880A9 (en) | 2003-06-04 | 2006-05-04 | Barrett Anthony G M | Synthetic process for trans-aminocyclohexyl ether compounds |
WO2005018635A2 (en) | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
US20070197632A1 (en) | 2003-10-31 | 2007-08-23 | Cardiome Pharma Corp | Aminocyclohexyl ether compounds and uses thereof |
US7345087B2 (en) | 2003-10-31 | 2008-03-18 | Cardiome Pharma Corp. | Aminocyclohexyl ether compounds and uses thereof |
US7789873B2 (en) * | 2004-08-02 | 2010-09-07 | Coloplast A/S | Urinary catheter assembly |
-
1999
- 1999-04-01 AU AU30215/99A patent/AU751772C/en not_active Expired
- 1999-04-01 BR BRPI9909282 patent/BRPI9909282B8/pt unknown
- 1999-04-01 RO ROA200000939A patent/RO121028B1/ro unknown
- 1999-04-01 KR KR1020007010894A patent/KR100631299B1/ko not_active IP Right Cessation
- 1999-04-01 ID IDW20002226A patent/ID27178A/id unknown
- 1999-04-01 PT PT99911550T patent/PT1087934E/pt unknown
- 1999-04-01 CA CA2326777A patent/CA2326777C/en not_active Expired - Lifetime
- 1999-04-01 AT AT99911550T patent/ATE260240T1/de active
- 1999-04-01 MX MXPA00009593A patent/MXPA00009593A/es active IP Right Grant
- 1999-04-01 IL IL13871999A patent/IL138719A0/xx not_active IP Right Cessation
- 1999-04-01 SK SK1437-2000A patent/SK285908B6/sk not_active IP Right Cessation
- 1999-04-01 DE DE69915063T patent/DE69915063T2/de not_active Expired - Lifetime
- 1999-04-01 HU HU0102613A patent/HU229993B1/hu active Protection Beyond IP Right Term
- 1999-04-01 DK DK99911550T patent/DK1087934T3/da active
- 1999-04-01 NZ NZ507169A patent/NZ507169A/xx not_active IP Right Cessation
- 1999-04-01 EP EP99911550A patent/EP1087934B1/en not_active Expired - Lifetime
- 1999-04-01 JP JP2000541135A patent/JP4334766B2/ja not_active Expired - Lifetime
- 1999-04-01 RU RU2000127720/04A patent/RU2252933C2/ru active
- 1999-04-01 TR TR2000/02796T patent/TR200002796T2/xx unknown
- 1999-04-01 PL PL343425A patent/PL197293B1/pl unknown
- 1999-04-01 ES ES99911550T patent/ES2217742T3/es not_active Expired - Lifetime
- 1999-04-01 EP EP04002165A patent/EP1422217A3/en not_active Withdrawn
- 1999-04-01 EE EEP200000583A patent/EE04548B1/xx active Protection Beyond IP Right Term
- 1999-04-01 CZ CZ20003485A patent/CZ302147B6/cs not_active IP Right Cessation
- 1999-04-01 WO PCT/CA1999/000280 patent/WO1999050225A1/en not_active Application Discontinuation
- 1999-04-01 CN CN998066826A patent/CN1217918C/zh not_active Expired - Lifetime
- 1999-04-01 DE DE122010000052C patent/DE122010000052I1/de active Pending
-
2000
- 2000-09-20 IS IS5632A patent/IS2648B/is unknown
- 2000-09-29 NO NO20004897A patent/NO321130B1/no not_active IP Right Cessation
-
2001
- 2001-12-28 HK HK01109173A patent/HK1038345A1/xx not_active IP Right Cessation
-
2003
- 2003-09-29 US US10/674,684 patent/US7101877B2/en not_active Expired - Lifetime
-
2006
- 2006-05-08 JP JP2006129715A patent/JP2006306878A/ja active Pending
- 2006-06-09 US US11/450,921 patent/US20070004718A1/en not_active Abandoned
-
2007
- 2007-11-21 US US11/944,282 patent/US7534790B2/en not_active Expired - Lifetime
-
2009
- 2009-04-15 US US12/424,450 patent/US7875611B2/en not_active Expired - Fee Related
-
2010
- 2010-11-29 LU LU91761C patent/LU91761I2/fr unknown
- 2010-12-03 CY CY2010018C patent/CY2010018I2/el unknown
- 2010-12-14 NO NO2010023C patent/NO2010023I2/no unknown
- 2010-12-16 US US12/970,532 patent/US20110207730A1/en not_active Abandoned
- 2010-12-30 FR FR10C0057C patent/FR10C0057I2/fr active Active
-
2011
- 2011-01-20 BE BE2011C002C patent/BE2011C002I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK285908B6 (sk) | Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe | |
US7687536B2 (en) | Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics | |
US7259184B2 (en) | Ion channel modulating compounds and uses thereof | |
US7105534B2 (en) | Imidazo[1,2-α]pyridine ether compounds as ion channel modulators | |
US8008342B2 (en) | Ion channel modulating compounds and uses thereof | |
CA2268590A1 (en) | Ion channel modulating compounds and uses thereof | |
US6979685B1 (en) | Cycloalkyl amine compounds and uses thereof | |
WO2000047547A2 (en) | Cycloalkyl amine compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of an spc |
Free format text: PRODUCT NAME: VERNAKALANT; REGISTRATION NO/DATE: EU/1/10/645/001 - EU/1/10/645/002 20100901 Spc suppl protection certif: 5001-2011 Filing date: 20110103 |
|
SPCG | Grant of an spc |
Free format text: PRODUCT NAME: VERNAKALANT; REGISTRATION NO/DATE: EU/1/10/645/001 - EU/1/10/645/002 20100901 Spc suppl protection certif: 101 5001-2011 Filing date: 20110103 Expiry date: 20190402 Extension date: 20240402 |
|
SPCT | Transfer of rights of an spc |
Free format text: OWNER: CORREVIO CANADA CORP, CA; FORMER OWNER: CARDIOME PHARMA CORP, CA Spc suppl protection certif: 101 5001-2011 Effective date: 20190327 |
|
PC4A | Assignment and transfer of rights |
Owner name: CORREVIO CANADA CORP., VANCOUVER, CA Free format text: FORMER OWNER: CARDIOME PHARMA CORP., VANCOUVER, CA Effective date: 20190328 Owner name: CORREVIO INTERNATIONAL SARL, GENEVA, CH Free format text: FORMER OWNER: CORREVIO CANADA CORP., VANCOUVER, CA Effective date: 20190328 |
|
MK4A | Patent expired |
Expiry date: 20190401 |